Screening by maternal serum markers for Down's syndrome.
- Author:
Jun-tao LIU
1
;
Na HAO
;
Nian-hu SUN
;
Feng-yun WANG
;
Yun-hua XU
;
Ming-ying GAI
;
Xu-ming BIAN
;
Jian-qiu YANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Amniocentesis; Biomarkers; blood; Chorionic Gonadotropin, beta Subunit, Human; blood; Down Syndrome; diagnosis; prevention & control; Female; Fetal Diseases; diagnosis; prevention & control; Humans; Mass Screening; Pregnancy; blood; Pregnancy-Associated Plasma Protein-A; analysis; Prenatal Diagnosis; methods; alpha-Fetoproteins; analysis
- From: Acta Academiae Medicinae Sinicae 2003;25(2):156-159
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the optimal method of screening for Down's syndrome (DS) with maternal serum mankers.
METHODSScreening by maternal serum markers for Down's syndrome was offered to all 2886 pregnant women in Peking Union Medical Hospital during 1996.11-2001.3. Alpha-fetoprotein (AFP), human chorionic gonadotrophin (free beta-HCG) were used as markers during the first year of pregnancy. Alpha-fetoprotein, free human chorionic gonadotrophin (HCG) and pregnancy-associated plasma protein A (PAPP-A) were used as mid pregnancy and first-trimester markers in next three years. Amniocentesis and (CVS) were done in those defined as risk cases.
RESULTSThe detection rate of Down's syndrome by maternal serum markers was 3.8% (11/2886). The proportion of false positive results in group of triple markers (alpha FP, free beta-HCG, PAPP-A) was 5%.
CONCLUSIONSThe PAPP-A was a good marker to detect Down's syndrome in early pregnancy and may be used to predict the outcome during mid trimester of pregnancy. The AFP and free beta-HCG can be useful markers to detect Down's syndrome and fetal abnormality. While prenatal diagnostics can be shifted to an early pregnant period.
